Agonists of TREM2 would be expected to repair cerebral ischemia/reperfusion injury, making TREM2 an attractive new clinical target for the treatment of ischemic stroke and other cerebrovascular diseases. The gene discussed is TREM2; the disease is ischemic stroke.